$5.77
12.84%
Nasdaq, Nov 16, 02:28 pm EST. Market open.
ISIN
US48669G1058
Symbol
KZIA

Kazia Therapeutics Ltd Sponsored ADR Stock price

$6.62
-1.42 17.66% 1M
-7.38 52.71% 6M
-0.27 3.92% YTD
-0.67 9.19% 1Y
-26.27 79.87% 3Y
-552.88 98.82% 5Y
-313.38 97.93% 10Y
-3,352.99 99.80% 20Y
Nasdaq, Closing price Fri, Nov 13 2026
-0.33 4.75%
ISIN
US48669G1058
Symbol
KZIA
Industry

Is Kazia Therapeutics Ltd Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$79.4m
Enterprise Value
$42.1m
Net debt
positive
Cash
$47.0m
Shares outstanding
5.7b
Valuation
P/E
negative
P/S | estimate
467.2 | 199.1
EV/Sales | estimate
247.4 | 105.4
EV/FCF | ex SBC
negative | negative
P/B
2.5
Financial Health
Equity Ratio
-137.0%
Return on Equity
249.4%
ROCE
-42.1%
ROIC
468.2%
Debt/Equity
0.3
Share-Based Compensation & Dilution
SBC | % of Revenue
$2.8m | 1,658.8%
SBC as % of FCF
-
SBC Growth 1Y
642.1%
Share Count Growth 1Y
5,761.4%
Shareholder Yield
-
Financials
Revenue | estimate
$170.0k | $398.9k
EBITDA
-
EBIT
$-13.3m
Net Income
$-15.4m
Free Cash Flow | ex SBC
$-760.0k | $-3.6m
Growth
Revenue | estimate
-89.3% | 398.6%
EBITDA
-
EBIT
34.2%
Net Income
19.8%
Free Cash Flow
90.4%
Margin
Gross
-
EBITDA
-
EBIT
-7,995.5%
Net
-9,257.3%
Free Cash Flow | ex SBC
-454.9% | -2,148.1%
More
EPS
$0.0
FCF per Share
$0.0
Short interest
9.3%
Employees
6
Rev per Employee
$10.0k

Kazia Therapeutics Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Kazia Therapeutics Ltd Sponsored ADR forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Kazia Therapeutics Ltd Sponsored ADR forecast:

Buy
92%
Hold
8%

Kazia Therapeutics Ltd Sponsored ADR Events

Past Events
SEP
1
Special Call - Kazia Therapeutics Limited
3 months ago

Financial data from Kazia Therapeutics Ltd Sponsored ADR

Dec '25
+/-
%
0.17 0.17
89% 89%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 8.24 8.24
14% 14%
4,847%
- Research and Development Expense 5.44 5.44
54% 54%
3,200%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -13 -13
34% 34%
-7,844%
Net Profit -15 -15
20% 20%
-9,082%

In millions USD.

Don't miss a Thing! We will send you all news about Kazia Therapeutics Ltd Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kazia Therapeutics Ltd Sponsored ADR Stock News

Neutral
PRNewsWire
●
4 days ago
SYDNEY, Nov. 12, 2026 /PRNewswire/ -- Kazia Therapeutics Limited  (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that it will host a virtual event on Wednesday, December 2, 2026 at 4:00 PM ET featuring management's o...
Neutral
PRNewsWire
●
11 days ago
Recognition Highlights Kazia's Focus on Overcoming Treatment Resistance in Cancer SYDNEY, Nov. 5, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, has been named "Drug Discovery Company ...
Neutral
PRNewsWire
●
14 days ago
Presentations to Explore Paxalisib's Differentiated Tumor and Immune Reprogramming Activity SYDNEY, Nov. 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that two abst...
More Kazia Therapeutics Ltd Sponsored ADR News

Company Profile

Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Head office Australia
CEO Dr. Friend
Employees 6
Founded 1994
Website www.kaziatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today